[HTML][HTML] Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed …
AD Schimmer, EH Estey, G Borthakur… - Journal of Clinical …, 2009 - ncbi.nlm.nih.gov
AD Schimmer, EH Estey, G Borthakur, BZ Carter, GJ Schiller, MS Tallman, JK Altman…
Journal of Clinical Oncology, 2009•ncbi.nlm.nih.govPhase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense
Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or
Primary Refractory Acute Myeloid Leukemia - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main
Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide
Journal List J Clin Oncol PMC5073380 Other Formats PDF (122K) Actions Cite Collections …
Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or
Primary Refractory Acute Myeloid Leukemia - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main
Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User Guide
Journal List J Clin Oncol PMC5073380 Other Formats PDF (122K) Actions Cite Collections …
Abstract
Purpose
X-linked inhibitor of apoptosis protein (XIAP) is an inhibitor of caspases 3 and 9 which are overexpressed in acute myeloid leukemia (AML) and may contribute to chemoresistance. We report on a phase I/II trial of the XIAP antisense oligonucleotide
ncbi.nlm.nih.gov